Cargando…

Wnt inhibitors reduce the unfolded protein response and enhance bortezomib-induced cell death in multiple myeloma

Detalles Bibliográficos
Autores principales:	Spaan, Ingrid, van Nieuwenhuijzen, Niels, Kimman, Thomas, Rockx-Brouwer, Dedeke, Tieland, Ralph G., Maurice, Madelon M., Minnema, Monique C., Raymakers, Reinier A., Peperzak, Victor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111341/ https://www.ncbi.nlm.nih.gov/pubmed/36459495 http://dx.doi.org/10.1182/bloodadvances.2022008442

Ejemplares similares

Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential
por: Spaan, Ingrid, et al.
Publicado: (2018)

Multiple Myeloma Relapse Is Associated with Increased NFκB Pathway Activity and Upregulation of the Pro-Survival BCL-2 Protein BFL-1
por: Spaan, Ingrid, et al.
Publicado: (2021)

Targeting B-cell maturation antigen increases sensitivity of multiple myeloma cells to MCL-1 inhibition
por: Cuenca, Marta, et al.
Publicado: (2021)

Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients
por: Oostvogels, Rimke, et al.
Publicado: (2018)

Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis
por: van Nieuwenhuijzen, Niels, et al.
Publicado: (2021)

EBV-related lymphoma after long-term daratumumab treatment: a case report
por: Verpoorte-Botden, Ilse P. G., et al.
Publicado: (2020)

Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response
por: Nikesitch, N, et al.
Publicado: (2016)

Phosphatase PP2A enhances MCL-1 protein half-life in multiple myeloma cells
por: Slomp, Anne, et al.
Publicado: (2021)

Serpin B9 controls tumor cell killing by CAR T cells
por: Kimman, Thomas, et al.
Publicado: (2023)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Effect of bortezomib on proliferation and apoptosis of myeloma cells by activating Wnt/β-catenin signaling pathway
por: Dai, Yanling, et al.
Publicado: (2020)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Clinical outcomes of bortezomib-based therapy in myeloma
por: Djebbari, Faouzi, et al.
Publicado: (2018)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

Spliced XBP1 Levels Determine Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitor Bortezomib Independent of the Unfolded Protein Response Mediator GRP78
por: Borjan, Bojana, et al.
Publicado: (2020)

Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma
por: Slomp, Anne, et al.
Publicado: (2018)

Bortezomib: the evidence of its clinical impact in multiple myeloma
por: Lancaster, Simon
Publicado: (2006)

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
por: Petrucci, Maria Teresa, et al.
Publicado: (2014)

Bortezomib-induced painful neuropathy in patients with multiple myeloma
por: Bilińska, Małgorzata, et al.
Publicado: (2013)

Tumor lysis syndrome in multiple myeloma treated with bortezomib
por: Dhanraj, K. M., et al.
Publicado: (2014)

BAFF is involved in macrophage-induced bortezomib resistance in myeloma
por: Chen, Jing, et al.
Publicado: (2017)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2017)

A feline case of multiple myeloma treated with bortezomib
por: Tani, Hiroyuki, et al.
Publicado: (2022)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
por: Han, Joseph, et al.
Publicado: (2023)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
por: Andersen, Kristian T., et al.
Publicado: (2020)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
por: O’Connor-Byrne, N., et al.
Publicado: (2019)

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
por: Richard, Shambavi, et al.
Publicado: (2021)

β-catenin inhibitors ICG-001 and pyrvinium sensitize bortezomib-resistant multiple myeloma cells to bortezomib
por: Wu, Cuicui
Publicado: (2022)

Structure-Function Analysis of DipA, a Francisella tularensis Virulence Factor Required for Intracellular Replication
por: Chong, Audrey, et al.
Publicado: (2013)

Falsely decreased ferritin concentrations in two patients with haemophagocytic lymphohistiocytosis: A case report
por: Roozen, Geert, et al.
Publicado: (2018)

P857: BORTEZOMIB- AND CARFILZOMIB-RESISTANT MYELOMA CELLS SHOW INCREASED ACTIVITY OF ALL THREE ARMS OF UNFOLDED PROTEIN RESPONSE AND ENRICHMENT OF SIRTUIN SIGNALING PATHWAY
por: Kubicki, T., et al.
Publicado: (2022)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

Low Dose Vaccination with Attenuated Francisella tularensis Strain SchuS4 Mutants Protects against Tularemia Independent of the Route of Vaccination
por: Rockx-Brouwer, Dedeke, et al.
Publicado: (2012)

Construction of a Vero Cell Line Expressing Human ICAM1 for the Development of Rhinovirus Vaccines
por: van den Braak, Wouter Johannes Petrus, et al.
Publicado: (2022)

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
por: Spencer, Andrew, et al.
Publicado: (2018)

Synergistic Efficacy of the Demethylation Agent Decitabine in Combination With the Protease Inhibitor Bortezomib for Treating Multiple Myeloma Through the Wnt/β-Catenin Pathway
por: Jin, Yulong, et al.
Publicado: (2019)

Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma
por: Lee, Won-Seop, et al.
Publicado: (2011)

Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma
por: Painuly, Utkarsh, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1778optd8aco30cj2lnpjoemfg